A March 4 hearing before the House Committee on Oversight and Government Reform, designed to shed light on the appropriateness of general screening for prostate cancer, highlighted the controversy about the issue.
Those who testified included proponents of such screening, which involves the prostate-specific antigen (PSA) test, and those who oppose it because of the unreliability of PSA testing for identifying harmful cancers. “There is a high degree of public awareness of the need for regular screening for certain kinds of cancers, notably breast cancer, prostate cancer, and colon cancer,” said Committee Chairman Rep Edolphus Towns (D, NY) in prepared remarks. “However, this widespread belief is now being debated.”
Mitka M. PSA Screening Debated. JAMA. 2010;303(14):1358. doi:10.1001/jama.2010.371
Customize your JAMA Network experience by selecting one or more topics from the list below.